(Q40104510)

17 September 2017

1 reference

title

Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs (English)

1 reference

17 September 2017

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

22 August 2023

author name string

G. Powis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6181872

22 August 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6181872

22 August 2023

publication date

1 June 1982

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:S0305737282800121?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

https://api.elsevier.com/content/article/PII:S0305737282800121?httpAccept=text/plain

22 August 2023

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

22 August 2023

published in

Cancer Treatment Reviews

1 reference

17 September 2017

9

1 reference

17 September 2017

85-124

1 reference

17 September 2017

2

1 reference

Preliminary Pharmacokinetics of Streptozotocin, an Antineoplastic Antibiotic

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Kinetics of intravenous melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Plasma half-life of cytosine arabinoside in patients with leukaemia--the effect of uridine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

The pharmacokinetics of [3H]-vincristine in man

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Antineoplastic drugs: clinical pharmacology and therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Pharmacokinetics and metabolism of adriamycin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

High-pressure liquid chromatographic analysis of ftorafur and its metabolites in biological fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma.A clinical and pharmacology report

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

STUDIES OF FLUORINATED PYRIMIDINES. XVIII. THE DEGRADATION OF 5-FLUORO-2'-DEOXYURIDINE AND RELATED COMPOUNDS BY NUCLEOSIDE PHOSPHORYLASE.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Use of Serum Creatinine Concentrations to Determine Renal Function1

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Liver disease and drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Protein Binding and Kinetics of Drugs in Liver Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Influence of acute viral hepatitis on phenytoin kinetics and protein binding

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Hepatic First-pass Metabolism in Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

The clinical pharmacology of methotrexate.new applications of an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

(131-I)ALBUMIN TURNOVER AND LOSS OF PROTEIN INTO THE SPUTUM IN CHRONIC BRONCHITIS

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

The disposition of cyclophosphamide in a group of myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Determinants of serum antipyrine half-lives in patients with liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Systemic methotrexate toxicity. A pharmacological study of its occurrence after intrathecal administration in a patient with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

A STUDY OF PLASMA PROTEIN VARIATIONS IN SURGICAL PATIENTS.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Combination chemotherapy with adriamycin and streptozotocin; II. Clinicopharmacologic correlation of augmented adriamycin toxicity caused by streptozotocin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Combination chemotherapy with adriamycin and streptozotocin; I. Clinical results in patients with advanced sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Hydrolysis and Protein Binding of Melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Pharmacokinetics of Creatinine in Man and Its Implications in the Monitoring of Renal Function and in Dosage Regimen Modifications in Patients with Renal Insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

THE PHYSIOLOGIC DISPOSITION OF 5-FLUOROURACIL AND 5-FLUORO-2'-DEOXYURIDINE IN MAN

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Pharmacokinetics of cyclophosphamide in man

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Correlation of serum creatinine concentration and kanamycin half-life. Therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Drug dosage in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyU-l-nitrosourea (BCNU) in man and animals

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Decreased half life of cyclophosphamide in patients under continual treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Studies with allopurinol in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Renal clearance of oxipurinol, the chief metabolite of allopurinol

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

High-dose intravenous and hepatic artery infusions of thymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Renal Failure, Drug Pharmacokinetics and Drug Action

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Renal excretion of sulphadimidine in normal and uraemic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

A phase I study of cytembena

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Kinetics and Mechanisms of Drug Action on Microorganisms XXIII: Microbial Kinetic Assay for Fluorouracil in Biological Fluids and Its Application to Human Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Drug Kinetics and Hepatic Blood Flow

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Drug elimination and apparent volume of distribution in multicompartment systems

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Kinetics of cis-dichlorodiammineplatinum

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Clinical toxicity of chloridazepoxide and diazepam in relation to serum albumin concentration: A report from the Boston collaborative drug surveillance Program

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Clinical Pharmacokinetics of Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Intrahepatic Portasystemic Shunting in Cirrhotic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Kinetics of gallium nitrate, a new anticancer agent

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

1 reference

7 January 2021

Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Quantitative Assessment of Hepatic Function by Breath Analysis after Oral Administration of [^14C]aminopyrine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

GLC Determination for Ftorafur in Biological Fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Clinical kinetics on intact cisplatin and some related species

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Phase I studies on chlorozotocin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Daunorubicin metabolism in acute nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Pharmacokinetics of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Influence of range of renal function and liver disease on predictability of creatinine clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Pharmacokinetics of methotrexate administered via the hepatic artery

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Biliary excretion of vincristine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Synthesis and biologic evaluation of major metabolites of N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Glomerular filtration rate and creatinine clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Pharmacokinetics of gallium nitrate in man

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Clinical toxicologic and pharmacologic studies of gallium nitrate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Renal function and the rate of disappearance of methotrexate from serum

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Determination of N-(Phosphonacetyl)-l-Aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Selective lethal effect of thymidine on human and mouse tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

The effect of organic acids on renal clearance of methotrexate in man

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Hepatic toxicity of nitrosourea analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Metabolism and Disposition of Baker's Antifolate (NSC-139105), Ftorafur (NSC-148958), and Dichlorallyl Lawsone (NSC-126771) in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

The plasma half-life of antipyrine in chromic uraemic and normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Clinical aspects of the excretion of alkylating cyclophosphamide metabolites in the urine of tumor bearing patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Metabolism of amylobarbitone in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Hydroxylation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) by rat liver microsomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

The effect of neoplastic and allied diseases on the concentrations of the plasma proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

The Biotransformation of Cyclophosphamide in Man: Analysis of the Variation in Normal Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Vincristine-Induced Quadriparesis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Pharmacokinetics of the fluoropyrimidines: implications for their clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Pharmacokinetics of oral and intravenous fluorouracil in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Dose-dependent pharmacokinetics and cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Cisplatin pharmacokinetics in a patient with renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Effects of Renal Disease upon Drug Disposition

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Drug therapy in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Bilary disposition of adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Phase I studies with Baker's Antifol (BAF) (NSC 139105)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Albumin synthesis (second of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Influence of route of administration on drug availability

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Clearance concepts in pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

m-AMSA and PALA: two new agents in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Nephrotoxicity of nitrosoureas

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Streptozotocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Clinical antitumor activity and toxicity of streptozotocin (NSC-85998)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Clinical Pharmacokinetics of Methotrexate1

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Lidocaine Pharmacokinetics in Advanced Heart Failure, Liver Disease, and Renal Failure in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Commentary: a physiological approach to hepatic drug clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Drug pharmacokinetics in cardiac and hepatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Hepatic disease and drug pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980012-1

7 January 2021

Bleomycin pharmacokinetics in man. I. Intravenous administration

7

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

The effect of phenobarbital on cyclophosphamide antitumor activity

22 August 2023

8

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans

22 August 2023

9

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Pharmacokinetics and metabolism of ftorafur in man

22 August 2023

11

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Clinical pharmacology of cyclophosphamide

22 August 2023

13

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Initial clinical studies with bruceantin

22 August 2023

16

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Clinical studies with rubidazone

22 August 2023

23

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans

22 August 2023

32

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Pathophysiological Factors Influencing Drug Kinetics

22 August 2023

48

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

The fate of antipyrine in man

22 August 2023

50

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Some observations on the human pharmacology of methotrexate

22 August 2023

56

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis

22 August 2023

62

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model

22 August 2023

63

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

The disposition of ftorafur in rats after intravenous administration

22 August 2023

75

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Pharmacokinetics of the protein antitumor antibiotic neocarzinostatin after bolus injection in humans

22 August 2023

79

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Phase II evaluation of triazinate in patients with metastatic lung cancer

22 August 2023

80

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Clinical effects and pharmacokinetics of different dosage schedules of adriamycin

22 August 2023

81

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Studies on the clinical pharmacology of bleomycin

22 August 2023

83

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Kinetics of cyclophosphamide biotransformation in vivo

22 August 2023

93

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans

22 August 2023

101

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Pharmacologic studies of tritiated cytosine arabinoside (NSC-63878) in children

22 August 2023

107

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Clinical pharmacology of IMPY by radioimmunoassay

22 August 2023

111

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin

22 August 2023

117

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Phase I evaluation of dianhydrogalactitol (NSC-132313)

22 August 2023

131

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Evidence for toxicologic activity of ftorafur independent of conversion to 5-fluorouracil

22 August 2023

140

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Microsomal metabolism of nitrosoureas

22 August 2023

144

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Phase I trial of pentamethylmelamine: a clinical and pharmacologic study

22 August 2023

163

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Phenobarbital effects on cyclophosphamide pharmacokinetics in man

22 August 2023

169

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Albumin metabolism in the nephrotic syndrome in adults

22 August 2023

171

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man

22 August 2023

187

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Phase I study on bruceantin administered on a weekly schedule

22 August 2023

193

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion

22 August 2023

194

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans

22 August 2023

198

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Mechanism of action and pharmacology studies with DTIC (NSC-45388)

22 August 2023

199

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Pharmacokinetics of Cyclophosphamide in Renal Failure

22 August 2023

214

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Phase I clinical evaluation of anguidine

22 August 2023

217

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study

22 August 2023

219

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Clinical pharmacologic effects of thymidine plus 5-FU

22 August 2023

229

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Pharmacology of the nitrosoureas: an overview

22 August 2023

230

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Pharmacokinetics of vindesine and vincristine in humans

22 August 2023

233

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Quantitation by gas chromatography-chemical ionization-mass spectrometry of phenylalanine mustard in plasma of patients

22 August 2023

234

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Estimation of Drug Elimination in Renal Failure

22 August 2023

237

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Clearance and biologic half-life as indices of intrinsic hepatic metabolism

22 August 2023

238

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Experimental and clinical studies on the formation of antibodies to neocarzinostatin, a new protein antibiotic

22 August 2023

253

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Pharmacokinetics of Cytembena in chronic renal impairment

22 August 2023

260

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Disposition of 5-fluorouracil after intravenous bolus doses of a commercial formulation to cancer patients

22 August 2023

264

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Clinical and pharmacological evaluation of triazinate in humans

22 August 2023

265

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia

22 August 2023

280

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

Phase II trial of methyl-GAG in advanced renal cancer

22 August 2023

295

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(82)80012-1

22 August 2023

Identifiers

1 reference

release_7hzsnqx6onaordiy2ij74yfski

17 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7hzsnqx6onaordiy2ij74yfski

24 November 2022

mapped directly with Wikidata item

1 reference